Rivastigmine in the Management of Delirium

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

February 29, 2016

Conditions
Delirium
Interventions
DRUG

Rivastigmine transdermal patch

One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped

DRUG

placebo patch

One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped

Trial Locations (1)

75013

Pitié Salpetriere Hospital, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER